Topic: monoclonal antibody
AgomAb Therapeutics is coming out of stealth with €21 million to develop agonistic monoclonal antibodies that could potentially treat a range of diseases.
University of Tennessee scientists have designed a CD19-targeting CAR-T for lupus and have shown encouraging results in a mouse study.
Purdue Pharma’s new R&D subsidiary, Imbrium Therapeutics, tapped TetraGenetics and its antibody discovery platform for non-opioid-based painkillers.
Aro Biotherapeutics raised $13 million to build its team and advance its centyrin pipeline, which includes a candidate for non-small cell lung cancer.
HiFiBiO Therapeutics has had a busy year, as pacts and raises abound, and it’s showing no signs of slowing down as it gets its checkbook out for an unusual French spinout.
A phase 2 study of Xencor’s lead antibody missed its primary endpoint in lupus, though the company described the data as worthy of future study.
Celgene is walking away from navicixizumab, a bispecific antibody that became OncoMed’s lead asset after midstage failures scuppered a couple of other candidates.
The series C round comes as Atreca gears up to move its lead solid tumor drug into the clinic and boost the throughput of its discovery engine.
Pfizer halted two phase 2 trials of its Duchenne muscular dystrophy drug domagrozumab after the main efficacy study failed its primary endpoint.
Y-mAbs Therapeutics filed to raise up to $92 million in its IPO to advance a pair of pivotal-stage meds for childhood brain cancers.